Mediclinic International PLC (MDC) Receives Consensus Recommendation of “Hold” from Analysts
Mediclinic International PLC (LON:MDC) has earned an average rating of “Hold” from the six brokerages that are presently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is GBX 428.50 ($5.60).
A number of research firms have recently commented on MDC. Bank of America upgraded Mediclinic International to a “neutral” rating in a report on Tuesday. Barclays dropped their price objective on Mediclinic International from GBX 460 ($6.01) to GBX 410 ($5.36) and set an “equal weight” rating on the stock in a report on Friday, April 12th.
Shares of LON MDC opened at GBX 316.10 ($4.13) on Tuesday. The company has a current ratio of 1.86, a quick ratio of 1.71 and a debt-to-equity ratio of 63.47. Mediclinic International has a 1-year low of GBX 293.10 ($3.83) and a 1-year high of GBX 645 ($8.43). The stock has a market cap of $2.33 billion and a price-to-earnings ratio of -15.42.
Mediclinic International Company Profile
Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers acute care, specialist-orientated, and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 17 private acute care hospitals and 4 clinics with approximately 1,805 inpatient beds in Switzerland; 49 acute care private hospitals and 2 day clinics in South Africa, and 3 hospitals in Namibia with approximately 8,131 inpatient beds; and 6 acute care private hospitals and 22 clinics with approximately 748 inpatient beds in the United Arab Emirates.
Recommended Story: Straddles
Receive News & Ratings for Mediclinic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International and related companies with MarketBeat.com's FREE daily email newsletter.